companies / r1therapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-14 json
| total_raised | 77,500,00077.5M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | Boston | |
| industry | unknown | |
| stage | series-a |
R1 Therapeutics develops AP306, a first-in-class pan phosphate-transporter inhibitor that blocks GI phosphate absorption to treat hyperphosphatemia in chronic kidney disease. It targets CKD patients on dialysis or post-transplant. Active-transporter blockade replaces 9-15 binder pills a day, backed by a $77.5M Series A led by DaVita Venture Group.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-03-17 | series-a | 77,500,00077.5M | null | ○ |
cloudflare, cloudflare bot management, hsts, react, remix, styled-components, web-vitals
| fact | status | src |
|---|---|---|
| Series A, $77.5M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |